JP2022519930A5 - - Google Patents
Info
- Publication number
- JP2022519930A5 JP2022519930A5 JP2021557396A JP2021557396A JP2022519930A5 JP 2022519930 A5 JP2022519930 A5 JP 2022519930A5 JP 2021557396 A JP2021557396 A JP 2021557396A JP 2021557396 A JP2021557396 A JP 2021557396A JP 2022519930 A5 JP2022519930 A5 JP 2022519930A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- chemotherapeutic agent
- doxorubicin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825017P | 2019-03-27 | 2019-03-27 | |
| US62/825,017 | 2019-03-27 | ||
| PCT/US2020/025532 WO2020198705A1 (en) | 2019-03-27 | 2020-03-27 | Combinations useful in a method for treating sarcoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519930A JP2022519930A (ja) | 2022-03-25 |
| JP2022519930A5 true JP2022519930A5 (enExample) | 2023-04-04 |
| JP7602481B2 JP7602481B2 (ja) | 2024-12-18 |
Family
ID=72609016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557396A Active JP7602481B2 (ja) | 2019-03-27 | 2020-03-27 | 肉腫を治療する方法に有用な組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220152024A1 (enExample) |
| EP (1) | EP3947379A4 (enExample) |
| JP (1) | JP7602481B2 (enExample) |
| CN (1) | CN114096537B (enExample) |
| AU (1) | AU2020248103A1 (enExample) |
| BR (1) | BR112021019170A2 (enExample) |
| CA (1) | CA3134648A1 (enExample) |
| EA (1) | EA202192349A1 (enExample) |
| IL (1) | IL286647A (enExample) |
| MX (1) | MX2021011688A (enExample) |
| WO (1) | WO2020198705A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (enExample) * | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| EP1351691A4 (en) * | 2000-12-12 | 2005-06-22 | Cytovia Inc | SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF |
| KR20090094148A (ko) * | 2006-12-20 | 2009-09-03 | 제이-씨 헬쓰 케어 리미티드 | 페길화 리포좀 독소루비신의 투여 방법 |
| PH12015501130B1 (en) * | 2012-11-21 | 2023-01-27 | Ptc Therapeutics Inc | Substituted reverse pyrimidine bmi-1 inhibitors |
| JP2021535198A (ja) * | 2018-08-17 | 2021-12-16 | ピーティーシー セラピューティクス， インコーポレイテッド | 膵臓癌を治療する方法 |
| KR20210151061A (ko) * | 2019-03-11 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형 |
-
2020
- 2020-03-27 CA CA3134648A patent/CA3134648A1/en active Pending
- 2020-03-27 CN CN202080039624.8A patent/CN114096537B/zh active Active
- 2020-03-27 US US17/441,355 patent/US20220152024A1/en not_active Abandoned
- 2020-03-27 MX MX2021011688A patent/MX2021011688A/es unknown
- 2020-03-27 JP JP2021557396A patent/JP7602481B2/ja active Active
- 2020-03-27 WO PCT/US2020/025532 patent/WO2020198705A1/en not_active Ceased
- 2020-03-27 AU AU2020248103A patent/AU2020248103A1/en not_active Abandoned
- 2020-03-27 EA EA202192349A patent/EA202192349A1/ru unknown
- 2020-03-27 BR BR112021019170A patent/BR112021019170A2/pt not_active Application Discontinuation
- 2020-03-27 EP EP20776386.3A patent/EP3947379A4/en not_active Withdrawn
-
2021
- 2021-09-23 IL IL286647A patent/IL286647A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2024133475A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| EA037152B1 (ru) | Способ лечения рака | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| AU2010235917A1 (en) | Combination of organic compounds | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| JP2016503035A (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| EP1757283B1 (en) | Antitumor effect fortifier, antitumor agent and method of therapy for cancer | |
| JP2020176071A (ja) | 血液がんの新規治療法及び新規治療剤 | |
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| US20220339162A1 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating desmoid tumors | |
| JP2024518426A5 (enExample) | ||
| EP3010508A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| EP4676454A1 (en) | Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy | |
| EP4676478A1 (en) | Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy | |
| JP6239745B2 (ja) | がんの処置のための、ｒｏ５５０３７８１及びカペシタビンの組み合わせ | |
| JP2022552336A (ja) | 造血器悪性腫瘍を治療するための併用療法 | |
| RU2004111287A (ru) | Применение 4-пиридилметилфталазинов для лечения рака | |
| HK40054116A (en) | Pharmaceutical combination preparation for treating terminal non-small cell lung cancer patients with brain metastasis |